vs
MARCUS CORP（MCS）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是Tarsus Pharmaceuticals, Inc.的1.3倍（$193.5M vs $151.7M），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $13.0M），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 18.2%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
MCS vs TARS — 直观对比
营收规模更大
MCS
是对方的1.3倍
$151.7M
营收增速更快
TARS
高出125.6%
2.8%
自由现金流更多
MCS
多$13.4M
$13.0M
两年增速更快
TARS
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $151.7M |
| 净利润 | — | $-8.4M |
| 毛利率 | — | — |
| 营业利润率 | 0.9% | -5.3% |
| 净利率 | — | -5.5% |
| 营收同比 | 2.8% | 128.4% |
| 净利润同比 | — | 63.8% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSTARS
| Q4 25 | $193.5M | $151.7M | ||
| Q3 25 | $210.2M | $118.7M | ||
| Q2 25 | $206.0M | $102.7M | ||
| Q1 25 | $148.8M | $78.3M | ||
| Q4 24 | $188.3M | $66.4M | ||
| Q3 24 | $232.7M | $48.1M | ||
| Q2 24 | $176.0M | $40.8M | ||
| Q1 24 | $138.5M | $27.6M |
净利润MCSTARS
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $16.2M | $-12.6M | ||
| Q2 25 | $7.3M | $-20.3M | ||
| Q1 25 | $-16.8M | $-25.1M | ||
| Q4 24 | $986.0K | $-23.1M | ||
| Q3 24 | $23.3M | $-23.4M | ||
| Q2 24 | $-20.2M | $-33.3M | ||
| Q1 24 | $-11.9M | $-35.7M |
营业利润率MCSTARS
| Q4 25 | 0.9% | -5.3% | ||
| Q3 25 | 10.8% | -12.2% | ||
| Q2 25 | 6.3% | -21.6% | ||
| Q1 25 | -13.7% | -33.5% | ||
| Q4 24 | -1.2% | -36.8% | ||
| Q3 24 | 14.1% | -52.3% | ||
| Q2 24 | 1.3% | -81.6% | ||
| Q1 24 | -12.0% | -136.5% |
净利率MCSTARS
| Q4 25 | — | -5.5% | ||
| Q3 25 | 7.7% | -10.6% | ||
| Q2 25 | 3.6% | -19.8% | ||
| Q1 25 | -11.3% | -32.1% | ||
| Q4 24 | 0.5% | -34.8% | ||
| Q3 24 | 10.0% | -48.7% | ||
| Q2 24 | -11.5% | -81.6% | ||
| Q1 24 | -8.6% | -129.4% |
每股收益（稀释后）MCSTARS
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.30 | ||
| Q2 25 | — | $-0.48 | ||
| Q1 25 | — | $-0.64 | ||
| Q4 24 | — | $-0.57 | ||
| Q3 24 | — | $-0.61 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $417.3M |
| 总债务越低越好 | $159.0M | $72.4M |
| 股东权益账面价值 | $457.4M | $343.4M |
| 总资产 | $1.0B | $562.2M |
| 负债/权益比越低杠杆越低 | 0.35× | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资MCSTARS
| Q4 25 | $23.4M | $417.3M | ||
| Q3 25 | $7.4M | $401.8M | ||
| Q2 25 | $14.9M | $381.1M | ||
| Q1 25 | $11.9M | $407.9M | ||
| Q4 24 | $40.8M | $291.4M | ||
| Q3 24 | $28.4M | $317.0M | ||
| Q2 24 | $32.8M | $323.6M | ||
| Q1 24 | $17.3M | $298.5M |
总债务MCSTARS
| Q4 25 | $159.0M | $72.4M | ||
| Q3 25 | $162.0M | $72.3M | ||
| Q2 25 | $179.9M | $72.1M | ||
| Q1 25 | $198.9M | $72.0M | ||
| Q4 24 | $159.1M | $71.8M | ||
| Q3 24 | $173.1M | $71.7M | ||
| Q2 24 | $175.7M | $71.6M | ||
| Q1 24 | $169.8M | $29.9M |
股东权益MCSTARS
| Q4 25 | $457.4M | $343.4M | ||
| Q3 25 | $454.3M | $335.1M | ||
| Q2 25 | $448.4M | $332.6M | ||
| Q1 25 | $441.8M | $342.5M | ||
| Q4 24 | $464.9M | $224.5M | ||
| Q3 24 | $462.3M | $237.5M | ||
| Q2 24 | $449.4M | $252.2M | ||
| Q1 24 | $459.3M | $275.2M |
总资产MCSTARS
| Q4 25 | $1.0B | $562.2M | ||
| Q3 25 | $1.0B | $534.6M | ||
| Q2 25 | $1.0B | $495.0M | ||
| Q1 25 | $1.0B | $500.8M | ||
| Q4 24 | $1.0B | $377.0M | ||
| Q3 24 | $1.0B | $376.3M | ||
| Q2 24 | $1.1B | $376.8M | ||
| Q1 24 | $1.0B | $349.3M |
负债/权益比MCSTARS
| Q4 25 | 0.35× | 0.21× | ||
| Q3 25 | 0.36× | 0.22× | ||
| Q2 25 | 0.40× | 0.22× | ||
| Q1 25 | 0.45× | 0.21× | ||
| Q4 24 | 0.34× | 0.32× | ||
| Q3 24 | 0.37× | 0.30× | ||
| Q2 24 | 0.39× | 0.28× | ||
| Q1 24 | 0.37× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $13.0M |
| 自由现金流率自由现金流/营收 | 13.6% | 8.6% |
| 资本支出强度资本支出/营收 | 11.6% | 4.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $989.0K | $-22.3M |
8季度趋势，按日历期对齐
经营现金流MCSTARS
| Q4 25 | $48.8M | $19.3M | ||
| Q3 25 | $39.1M | $18.3M | ||
| Q2 25 | $31.6M | $-29.4M | ||
| Q1 25 | $-35.3M | $-20.7M | ||
| Q4 24 | $52.6M | $-22.2M | ||
| Q3 24 | $30.5M | $-8.7M | ||
| Q2 24 | $36.0M | $-14.4M | ||
| Q1 24 | $-15.1M | $-37.8M |
自由现金流MCSTARS
| Q4 25 | $26.4M | $13.0M | ||
| Q3 25 | $18.2M | $16.3M | ||
| Q2 25 | $14.7M | $-30.4M | ||
| Q1 25 | $-58.3M | $-21.2M | ||
| Q4 24 | $27.1M | $-22.3M | ||
| Q3 24 | $12.0M | $-8.9M | ||
| Q2 24 | $16.1M | $-15.4M | ||
| Q1 24 | $-30.5M | $-38.0M |
自由现金流率MCSTARS
| Q4 25 | 13.6% | 8.6% | ||
| Q3 25 | 8.7% | 13.8% | ||
| Q2 25 | 7.1% | -29.6% | ||
| Q1 25 | -39.2% | -27.1% | ||
| Q4 24 | 14.4% | -33.5% | ||
| Q3 24 | 5.2% | -18.6% | ||
| Q2 24 | 9.2% | -37.8% | ||
| Q1 24 | -22.0% | -137.5% |
资本支出强度MCSTARS
| Q4 25 | 11.6% | 4.2% | ||
| Q3 25 | 9.9% | 1.6% | ||
| Q2 25 | 8.2% | 1.0% | ||
| Q1 25 | 15.5% | 0.8% | ||
| Q4 24 | 13.5% | 0.1% | ||
| Q3 24 | 7.9% | 0.6% | ||
| Q2 24 | 11.3% | 2.5% | ||
| Q1 24 | 11.1% | 0.6% |
现金转化率MCSTARS
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 4.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 53.31× | — | ||
| Q3 24 | 1.31× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
TARS
暂无分部数据
